Parathyroid Imaging: Which Test When
Choosing among sestamibi SPECT/CT, 4D-CT, choline PET/CT, and ultrasound for primary hyperparathyroidism
Quick Answer
Imaging in primary hyperparathyroidism is for localization, not diagnosis — the diagnosis is biochemical (hypercalcemia with inappropriately high PTH). The purpose of imaging is to guide minimally invasive parathyroidectomy by finding the culprit gland(s). No single modality is best in every setting: ultrasound and sestamibi SPECT/CT are the traditional first-line pair, ⁴ᴰ-CT excels at anatomic localization and reoperative cases, and ¹⁸F-fluorocholine PET/CT now has the highest sensitivity, especially for small glands, multigland disease, and prior negative imaging. The right choice depends on availability, body habitus, suspicion of multigland disease, and whether this is a first or repeat operation.
The decision in one place
Image to localize before a planned parathyroidectomy, not to make the diagnosis. Start with what your center does well — commonly ultrasound + sestamibi SPECT/CT. When those are negative, discordant, or the case is reoperative or multigland, escalate to ⁴ᴰ-CT and/or ¹⁸F-fluorocholine PET/CT, the latter now the most sensitive single test. Concordant positive localization on two modalities gives the surgeon the greatest confidence for a focused approach.
Head-to-head
| Modality | What it shows | Strengths | Limitations |
|---|---|---|---|
| Ultrasound | Anatomic (hypoechoic gland) | No radiation, cheap, first-line, adds thyroid assessment | Operator-dependent; blind to ectopic/mediastinal/retroesophageal glands |
| Sestamibi SPECT/CT (dual-phase/dual-tracer) | Functional (mitochondria-rich oxyphil cells retain tracer) | Widely available; SPECT/CT adds localization; detects ectopic glands | Lower sensitivity for small/multigland disease; false negatives with low oxyphil content |
| ⁴ᴰ-CT | Multiphase anatomic + enhancement kinetics | Excellent anatomic detail; strong in reoperative necks; fast | Higher radiation (thyroid dose); contrast; less "functional" specificity |
| ¹⁸F-fluorocholine PET/CT | Functional (choline uptake by hyperfunctioning tissue) | Highest sensitivity, small glands, multigland, prior-negative cases | Availability/cost; can be positive in thyroid nodes/inflammation |
How to sequence
A practical algorithm:
- First-line: ultrasound plus sestamibi SPECT/CT. Concordant positive findings on both → focused (minimally invasive) parathyroidectomy with intraoperative PTH monitoring.
- Negative or discordant first-line: proceed to ¹⁸F-fluorocholine PET/CT (best sensitivity) and/or ⁴ᴰ-CT. Fluorocholine PET is particularly valuable when sestamibi is negative or when multigland disease is suspected.
- Reoperative / persistent or recurrent disease: favor the most sensitive/anatomically precise combination — fluorocholine PET/CT and ⁴ᴰ-CT — because scar and altered anatomy degrade ultrasound and sestamibi.
Key pitfalls in selection
- Negative imaging does not contraindicate surgery. In biochemically proven primary hyperparathyroidism, a negative scan means the surgeon may plan a more extensive exploration — it does not overturn the diagnosis.
- Concurrent thyroid nodules cause both false positives (sestamibi, choline) and anatomic confusion (ultrasound); correlate carefully.
- Multigland disease/hyperplasia (e.g. MEN syndromes, secondary/tertiary hyperparathyroidism) is the classic reason single-gland localization fails — bias toward the most sensitive modality and expect bilateral exploration.
- Lithium and familial hypocalciuric hypercalcemia are biochemical mimics to exclude before imaging is even relevant.
Bottom line
Use imaging to plan the operation, choose first-line tests by local expertise (ultrasound + sestamibi SPECT/CT), and escalate to fluorocholine PET/CT (most sensitive) and ⁴ᴰ-CT for negative, discordant, multigland, or reoperative cases.
Self-Check
Q1. What is the purpose of parathyroid imaging, and what is it not for?
Answer: It is for localization to guide minimally invasive parathyroidectomy — not for diagnosis, which is biochemical (hypercalcemia with inappropriately high PTH). Negative imaging never overturns a biochemical diagnosis.
Q2. Which modality currently has the highest sensitivity, and in what situations is it most valuable?
Answer: ¹⁸F-fluorocholine PET/CT — most valuable for small glands, multigland disease, and prior negative/discordant imaging, and in reoperative necks.
Q3. What first-line combination gives the surgeon the most confidence for a focused approach?
Answer: Concordant positive ultrasound and sestamibi SPECT/CT — agreement on two modalities supports a focused (minimally invasive) parathyroidectomy with intraoperative PTH monitoring.
Q4. Why do sestamibi and ultrasound underperform in reoperative cases, and what is preferred?
Answer: Scar and altered anatomy degrade ultrasound and sestamibi; fluorocholine PET/CT and ⁴ᴰ-CT (sensitive/anatomically precise) are preferred for persistent or recurrent disease.
Key References
- SNMMI/EANM parathyroid scintigraphy and PET guidelines; society statements on parathyroid localization.
- Comparative cohorts and meta-analyses of ¹⁸F-fluorocholine PET/CT versus sestamibi and ⁴ᴰ-CT for primary hyperparathyroidism.
Evidence & sources
https://nuc.med/parathyroid-imaging-selection/ Report an issue